VAPO | Jotup

Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)

Retrieved on:

onsdag, mars 20, 2024

Temperature, Logic, Organization, Partnership, Internet of things, Fraction of inspired oxygen, VAPO, Patient, SAN, Gateway, Internet, Hospital, HVT, IoMT, HIPAA, OTCQX, Data, Periodic breathing, SOC 2

SAN FRANCISCO, March 20, 2024 /PRNewswire/ -- Onymos, developer of the world's first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership. This partnership will help Vapotherm create a unique respiratory digital platform to meet its data visualization and device management goals for the Vapotherm HVT® 2.0 system in the acute care space as well as for future products in the home.

Key Points:

Through the Onymos Features-as-a-Service platform , Vapotherm accesses Onymos' suite of Internet of Things (IoT) features — including Onymos Edge, Onymos Access, and Onymos DataStore — to build a secure end-to-end solution to connect the HVT 2.0 fleet with the cloud.
It consists of a GoLang-based "Gateway" application, an Angular web dashboard for remote device management, and cloud storage for patient data.
The Onymos platform also supports many of the other most popular frameworks for web and mobile application development.
For more information on Onymos, its Features-as-a-Service platform, or how it can help your company realize its IoT or IoMT goals, visit Onymos.com .

Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE

Retrieved on:

fredag, mars 15, 2024

Hypercapnia, Respironics, VAPO, Business, Patient, Mechanical ventilation, Spirometry, Business development, Quality of life, Respiratory disease, OTCQX, NIV, COPD, FDA, HME, Hospital

EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Key Points:

EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.
Dr. Jessica Whittle, Chief Medical Officer of Vapotherm, emphasized the company's commitment to improving the lives of hypercapnic patients in the home.
"(1)
The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th.
Joe Army, President and CEO of Vapotherm, underscored the significance of the solution, stating, "Vapotherm is committed to supporting patients both in and out of the hospital.

Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exa

Retrieved on:

onsdag, mars 6, 2024

The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD.

Key Points:

The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD.
Acute exacerbations of COPD contribute to over 600K emergency room (ER) visits and 140K deaths annually in the US alone.
"This study concludes that high velocity therapy provides similar clinical results and statistically superior patient reported comfort compared to mask-based therapies."
(3)
Dr. Yamane was presented with the award at the 2024 Critical Care Congress on January 23rd, 2024, in Phoenix, AZ.

Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market

Retrieved on:

torsdag, februari 29, 2024

VAPO, Intensive care medicine, Social media, Hospital, Compressed air, USD, Ageing, Periodic breathing, HVT, Vapotherm, Health, Patient, Optimism, OTCQX, COPD, Pharmaceutical industry

With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."

Key Points:

With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."
These features facilitate optimal patient care in the most advanced hospitals as well as resource constrained environments.
With the approval of the new system in Brazil, Vapotherm is launching a new Portuguese website and social media campaign.
The Company attended in the XXVIII Brazilian Congress of Intensive Care Medicine, the largest event of its kind in Latin America, to collaborate with approximately three thousand clinicians.

OTC Markets Group Welcomes Vapotherm, Inc. to OTCQX

Retrieved on:

fredag, december 15, 2023

OTCQX, Periodic breathing, Vapotherm, Patient, VAPO, Security (finance)

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX: VAPO), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, has qualified to trade on the OTCQX® Best Market.

Key Points:

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX: VAPO), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, has qualified to trade on the OTCQX® Best Market.
Vapotherm, Inc. voluntarily transferred to OTCQX from the New York Stock Exchange.
Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets.
To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)

Retrieved on:

torsdag, december 14, 2023

Other Professional Services, Professional Services, Finance, New York Stock Exchange, NYSE, Security (finance), Exchange, Committee, VAPO

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the “Company”) — ticker symbol VAPO — from the NYSE.

Key Points:

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Vapotherm, Inc. (the “Company”) — ticker symbol VAPO — from the NYSE.
Trading in the Company’s common stock will be suspended immediately.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange.
The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX

Retrieved on:

torsdag, december 14, 2023

Shareholder, NYSE, OTC Markets Group, OTCQX, Patient, VAPO, Cryptocurrency, Vapotherm

EXETER, N.H., Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately.

Key Points:

EXETER, N.H., Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately.
Vapotherm anticipates that its common stock will begin trading on the OTCQX Market ("OTCQX"), the highest market tier operated by OTC Markets Group, Inc. on December 15, 2023 under its current symbol VAPO.
Investors are expected to continue to be able to access accurate information, including stock price quotes, and execute trades.
Stockholders will not be required to exchange any shares, and the Company expects electronic trading to be available without any material disruption.

Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month

Retrieved on:

tisdag, november 28, 2023

Respiratory Care Week, VAPO, HVT, Hospital, NYSE, Patient, Vapotherm, Health, Education, Nursing

The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.

Key Points:

The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.
Dr. Jessica Whittle, Chief Medical Officer at Vapotherm, shared her enthusiasm: "About 7,000 clinicians initially registered for our educational programs, and we are thrilled that even more participated as the value became more well-known.
Vapotherm is committed to partnering with clinicans to provide the highest level of patient care.
Dr. Whittle and Joe Army were both present at the American Association for Respiratory Care Congress to celebrate this accomplishment and educate about the HVT 2.0 system.

Vapotherm To Report Third Quarter 2023 Financial Results

Retrieved on:

onsdag, november 1, 2023

VAPO, Telephone, Security (finance), NYSE, Regulation Fair Disclosure, Regulation, Cryptocurrency, Vapotherm

EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.

Key Points:

EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.
ET to discuss the financial results and recent business developments.
To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
The webcast replay will be available on the Vapotherm website for 12 months following completion of the call.

Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas

Retrieved on:

onsdag, oktober 4, 2023

Computational fluid dynamics uses advanced computer algorithms to understand gas flow characteristics in changing and complex systems.

Key Points:

Computational fluid dynamics uses advanced computer algorithms to understand gas flow characteristics in changing and complex systems.
Vapotherm’s unique small bore design generates higher gas velocity distinguishing it from other forms of high flow cannulas.
The modeling confirmed that the higher velocity generated by the Vapotherm design results in improved CO2 flush compared to other cannulas.
( https://dl.astfe.org/conferences/tfec2023,1ee0374044f80bd3,2fec083b2a0b5... )
“This reaffirms that not all high flow devices are the same and shows the value of high velocity therapy for clearance of CO2 and flush of the upper airway,” said Brian Lawrence, Chief Technology Officer at Vapotherm.